CL2024001052A1 - Formulaciones y sistemas de erdafitinib para administración intravesical. - Google Patents

Formulaciones y sistemas de erdafitinib para administración intravesical.

Info

Publication number
CL2024001052A1
CL2024001052A1 CL2024001052A CL2024001052A CL2024001052A1 CL 2024001052 A1 CL2024001052 A1 CL 2024001052A1 CL 2024001052 A CL2024001052 A CL 2024001052A CL 2024001052 A CL2024001052 A CL 2024001052A CL 2024001052 A1 CL2024001052 A1 CL 2024001052A1
Authority
CL
Chile
Prior art keywords
formulations
erdafitinib
systems
intravesical administration
delivery systems
Prior art date
Application number
CL2024001052A
Other languages
English (en)
Inventor
Mamidi Srinivas
Daniel Karen
Giesing Dennis
Erna H Heyns Philip
Julien Maurits Andre Dhondt Jens
Alfons C Delaet Urbain
Original Assignee
Taris Biomedical Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Taris Biomedical Llc filed Critical Taris Biomedical Llc
Publication of CL2024001052A1 publication Critical patent/CL2024001052A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61J—CONTAINERS SPECIALLY ADAPTED FOR MEDICAL OR PHARMACEUTICAL PURPOSES; DEVICES OR METHODS SPECIALLY ADAPTED FOR BRINGING PHARMACEUTICAL PRODUCTS INTO PARTICULAR PHYSICAL OR ADMINISTERING FORMS; DEVICES FOR ADMINISTERING FOOD OR MEDICINES ORALLY; BABY COMFORTERS; DEVICES FOR RECEIVING SPITTLE
    • A61J3/00—Devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms
    • A61J3/10—Devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms into the form of compressed tablets
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/498—Pyrazines or piperazines ortho- and peri-condensed with carbocyclic ring systems, e.g. quinoxaline, phenazine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0034—Urogenital system, e.g. vagina, uterus, cervix, penis, scrotum, urethra, bladder; Personal lubricants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2009—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2095—Tabletting processes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M31/00—Devices for introducing or retaining media, e.g. remedies, in cavities of the body
    • A61M31/002—Devices for releasing a drug at a continuous and controlled rate for a prolonged period of time
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M2210/00—Anatomical parts of the body
    • A61M2210/10—Trunk
    • A61M2210/1078—Urinary tract
    • A61M2210/1085—Bladder

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Gynecology & Obstetrics (AREA)
  • Biomedical Technology (AREA)
  • Anesthesiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Reproductive Health (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Inorganic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Infusion, Injection, And Reservoir Apparatuses (AREA)

Abstract

Se proporcionan composiciones farmacéuticas sólidas que comprenden erdafitinib, procesos para fabricar dichas formulaciones y sistemas de administración de fármacos que comprenden dichas formulaciones, incluidos sistemas de administración intravesical. Sistemas de administración de fármacos que comprenden dichas formulaciones, incluidos sistemas de administración intravesical.
CL2024001052A 2021-10-12 2024-04-09 Formulaciones y sistemas de erdafitinib para administración intravesical. CL2024001052A1 (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202163254974P 2021-10-12 2021-10-12
US202163255387P 2021-10-13 2021-10-13
US202263311841P 2022-02-18 2022-02-18

Publications (1)

Publication Number Publication Date
CL2024001052A1 true CL2024001052A1 (es) 2024-10-04

Family

ID=84283144

Family Applications (1)

Application Number Title Priority Date Filing Date
CL2024001052A CL2024001052A1 (es) 2021-10-12 2024-04-09 Formulaciones y sistemas de erdafitinib para administración intravesical.

Country Status (14)

Country Link
US (1) US20240350485A1 (es)
EP (1) EP4415692A1 (es)
JP (1) JP2024538993A (es)
KR (1) KR20240099258A (es)
AU (1) AU2022365014A1 (es)
CA (1) CA3235311A1 (es)
CL (1) CL2024001052A1 (es)
CO (1) CO2024005250A2 (es)
IL (1) IL312063A (es)
JO (1) JOP20240078A1 (es)
MX (1) MX2024004488A (es)
PE (1) PE20242104A1 (es)
TW (1) TW202333720A (es)
WO (1) WO2023064830A1 (es)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20240145513A (ko) * 2022-02-18 2024-10-07 타리스 바이오메디컬 엘엘씨 에르다피티닙 제형 및 방광내 투여를 위한 삼투성 시스템
KR20250143348A (ko) * 2023-02-13 2025-10-01 타리스 바이오메디컬 엘엘씨 방광암 치료에 사용하기 위한 방광내 투여용 에르다피티닙
CN120731077A (zh) * 2023-02-17 2025-09-30 塔里斯生物医药公司 膀胱内施用厄达替尼以用于治疗膀胱癌
WO2025059602A1 (en) * 2023-09-14 2025-03-20 Taris Biomedical Llc Methods of treating bladder cancer using intravesical administration of erdafitinib

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4666828A (en) 1984-08-15 1987-05-19 The General Hospital Corporation Test for Huntington's disease
US4683202A (en) 1985-03-28 1987-07-28 Cetus Corporation Process for amplifying nucleic acid sequences
US4801531A (en) 1985-04-17 1989-01-31 Biotechnology Research Partners, Ltd. Apo AI/CIII genomic polymorphisms predictive of atherosclerosis
US5272057A (en) 1988-10-14 1993-12-21 Georgetown University Method of detecting a predisposition to cancer by the use of restriction fragment length polymorphism of the gene for human poly (ADP-ribose) polymerase
US5192659A (en) 1989-08-25 1993-03-09 Genetype Ag Intron sequence analysis method for detection of adjacent and remote locus alleles as haplotypes
EP0951541B1 (en) 1995-07-31 2005-11-30 Urocor, Inc. Biomarkers and targets for diagnosis, prognosis and management of prostate disease
US6218529B1 (en) 1995-07-31 2001-04-17 Urocor, Inc. Biomarkers and targets for diagnosis, prognosis and management of prostate, breast and bladder cancer
US7772872B2 (en) 2008-09-08 2010-08-10 Altera Corporation Multi-row block supporting row level redundancy in a PLD
CN102470237A (zh) 2009-06-26 2012-05-23 塔里斯生物医药公司 用于可植入药物递送装置的固体药物片剂
US8721621B2 (en) 2009-09-10 2014-05-13 Taris Biomedical, Inc. Systems and methods for deploying devices to genitourinary sites
US9017312B2 (en) 2009-09-10 2015-04-28 Taris Biomedical Llc Implantable device for controlled drug delivery
PL3884988T3 (pl) 2009-12-17 2025-09-08 Taris Biomedical Llc Urządzenie implantowalne z tolerancją wewnątrzpęcherzową
GB201007286D0 (en) 2010-04-30 2010-06-16 Astex Therapeutics Ltd New compounds
US9457176B2 (en) 2010-10-06 2016-10-04 Taris Biomedical Llc Implantable drug delivery device with bladder retention feature
JP5945544B2 (ja) 2010-10-06 2016-07-05 タリス バイオメディカル エルエルシー 時間選択的に生体吸収可能または崩壊可能な薬剤送達システムおよび方法
AU2012211960B2 (en) 2011-02-04 2016-12-01 Taris Biomedical Llc Implantable device for controlled release of low solubility drug
PT2968880T (pt) 2013-03-15 2025-07-07 Taris Biomedical Llc Dispositivos de aplicação de fármaco com componente permeável a fármaco
KR102470456B1 (ko) 2014-09-26 2022-11-23 얀센 파마슈티카 엔.브이. Fgfr 억제제를 사용한 치료에 반응할 암 환자를 확인하는 데 있어서 fgfr 돌연변이 유전자 패널의 사용
TWI719960B (zh) 2015-02-10 2021-03-01 英商阿斯迪克治療公司 新穎組成物
KR102658706B1 (ko) 2015-04-23 2024-04-17 타리스 바이오메디컬 엘엘씨 약물-투과성 성분을 구비한 약물 전달 장치 및 방법
MA55486A (fr) 2019-03-29 2022-02-09 Janssen Pharmaceutica Nv Inhibiteurs de la tyrosine kinase fgfr pour le traitement du carcinome urothélial
US20220296866A1 (en) * 2019-06-10 2022-09-22 Poly-Med, Inc. Methods, devices and compositions for local delivery
CN115103678A (zh) * 2020-02-12 2022-09-23 詹森药业有限公司 用于治疗高风险非肌层浸润性膀胱癌的fgfr酪氨酸激酶抑制剂

Also Published As

Publication number Publication date
KR20240099258A (ko) 2024-06-28
AU2022365014A1 (en) 2024-05-30
EP4415692A1 (en) 2024-08-21
JOP20240078A1 (ar) 2024-04-07
WO2023064830A1 (en) 2023-04-20
IL312063A (en) 2024-06-01
CA3235311A1 (en) 2023-04-20
MX2024004488A (es) 2024-07-10
JP2024538993A (ja) 2024-10-28
US20240350485A1 (en) 2024-10-24
TW202333720A (zh) 2023-09-01
PE20242104A1 (es) 2024-10-28
CO2024005250A2 (es) 2024-05-30

Similar Documents

Publication Publication Date Title
CL2024001052A1 (es) Formulaciones y sistemas de erdafitinib para administración intravesical.
LT3962455T (lt) Nauja farmacinė kompozicija, skirta vaistų tiekimui
ECSP19075134A (es) Sistemas de administración de liberación sostenida que comprenden ligantes que no dejan huellas
CL2018000705A1 (es) Método de cristalización y biodisponibilidad
BR112015018087A8 (pt) composto, composição farmacêutica e uso
BR112017008301A2 (pt) extratos de cannabis e métodos de sua preparação e uso
MX2020007625A (es) Inhibidor mtor, composicion farmaceutica y su uso.
MX2024010141A (es) Formulaciones de erdafitinib y sistemas osmoticos para administracion intravesical
MX2009010289A (es) Composiciones para administracion nasal.
PH12019500061A1 (en) Oral gastroretentive formulations and uses thereof
WO2019126216A8 (en) Pharmaceutical compositions comprising a floating interpenetrating polymer network forming system
EP4332100A4 (en) PHOSPHONYL DERIVATIVE AND COMPOSITION AND PHARMACEUTICAL USE THEREOF
AR116501A1 (es) Sistema de suministro de polímero líquido para administración extendida de drogas
CO2021013677A2 (es) Proceso para la fabricación de extractos bacterianos estables y su uso como fármacos
MX383077B (es) Composiciones farmaceuticas para la administracion intraocular que comprenden un agente antibacteriano y un agente antiinflamatorio.
ECSP21067816A (es) Formulaciones farmacéuticas
ECSP22036502A (es) Inhibidores del factor d del complemento para administraci?n oral
ZA201807446B (en) Improved drug formulations
ECSP22036455A (es) Inhibidores del factor d del complemento para administraci?n oral
WO2021062231A3 (en) Cannabinoid prodrug compounds
MX2026000796A (es) Composiciones de administracion mejorada de epinefrina y profarmacos
BR112022016506A2 (pt) Compósito de (hidr)óxido de metal, e, composição farmacêutica
IL317870A (en) Biopolymer formulations for drug delivery
BR112018012616A2 (pt) formulação galênica que compreende um fármaco tópico
MX2020006886A (es) Sistema para suministro de medicamento.